IOL Chemicals and Pharmaceuticals Limited — PPTs, 13-02-2025: Investor Presentation

**Financial Highlights**: For Q3 FY2025, IOL Chemicals and Pharmaceuticals reported total income of ₹527 Cr, slightly down from ₹528.8 Cr YoY. EBITDA for the quarter was ₹51 Cr, resulting in an EBITDA margin of 9.7%. Profit After Tax (PAT) decreased to ₹21 Cr, with a PAT margin of 3.9%. For the nine months ended December 2024, total income reached ₹1,569 Cr, reflecting a decrease from the previous year.

**Strategic Initiatives and Growth Drivers**: The company is focusing on expanding its non-Ibuprofen pharmaceutical segment, which has shown significant growth, contributing ₹431 Cr in FY24 compared to ₹35 Cr in FY18. IOLCP has also commenced production of Acetic Anhydride to support its backward integration strategy.

**Business Developments**: IOLCP has been awarded the Responsible Care® logo by the Indian Chemical Council for three years, emphasizing its commitment to safety and sustainability.

**Market Position and Competitive Advantage**: IOLCP maintains a leading position in the API market, being the largest producer of Ibuprofen globally with a 30% market share. Its strong focus on international markets and product diversification continues to bolster its competitive edge.

**Investor Implications**: With steady revenue streams and strategic growth in non-Ibuprofen products, investors should watch closely for opportunities in this evolving market. The overall outlook remains positive, despite facing margin pressures from competition and demand challenges.